Evidence map›Paper›PMID 27789528›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma.

Katherine E Poruk, Amanda L Blackford, Matthew J Weiss, John L Cameron, Jin He, Michael Goggins, Zeshaan A Rasheed, Christopher L Wolfgang, Laura D Wood

Registry-linked trialAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05298722 (Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer), which is not on this map. Cited by 72 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05298722 narecruitingnot on this mapstarted 2022, after this paper: background citation

Prediction of Surgical Resectability After FOLFIRINOX Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: the Role of Diffusion Weighted Magnetic Resonance Imaging, Radiomics and Liquid Biopsy

TypeinterventionalSponsorUniversity Hospital, GhentRan2022 to 2028Enrolled45ConditionsPancreatic CancerArmsImaging analysis of CT-scan and MRI with radiomics and genetic analysis of peripheral blood samples and questionnaires.
3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Circulating tumor cells in pancreatic cancer: more than liquid biopsy.Therapeutic advances in medical oncology · 2024
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. The Prognostic Significance of Circulating Tumor Cells in Patients with Pancreatobiliary Cancer.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023
    Article
  18. Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer.International journal of molecular sciences · 2023
    Review
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katherine E PorukDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Amanda L BlackfordDepartment of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Matthew J WeissDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
John L CameronDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Jin HeDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Michael GogginsDepartment of Gasteroenterology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Zeshaan A RasheedDepartment of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Christopher L WolfgangDepartment of Surgery, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland. cwolfga2@jhmi.edu ldwood@jhmi.edu.
Laura D WoodDepartment of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland. cwolfga2@jhmi.edu ldwood@jhmi.edu.

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI THOMPSON, ELIZABETH D · 1993 to 2022
$54.6M
Clinical and Laboratory Research Training for Surgical OncologistsT32CA126607 · NCI · JOHNS HOPKINS UNIVERSITY · PI CAMERON, ANDREW M. · 2008 to 2024
$6.0M
Validation and Fine-Scale Mapping of Pancreatic Cancer Susceptibility Loci (Study)R01CA154823 · NCI · JOHNS HOPKINS UNIVERSITY · PI KLEIN, ALISON P · 2011 to 2020
$5.7M
Using Markers to Improve Pancreatic Cancer ScreeningR01CA176828 · NCI · JOHNS HOPKINS UNIVERSITY · PI GOGGINS, MICHAEL G. · 2013 to 2024
$4.1M
Characterization of the Molecular Determinants of High-Grade Dysplasia in Pancreatic Cancer Precursor LesionsK08DK107781 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI WOOD, LAURA DELONG · 2016 to 2020
$846k
NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA154823NCI NIH HHS R01 CA176828NCI NIH HHS T32 CA126607NIDDK NIH HHS K08 DK107781
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AC133 AntigenAdenocarcinomaAdultAgedAged, 80 and overAldehyde DehydrogenaseBiomarkers, TumorCarcinoma, Pancreatic DuctalDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansHyaluronan ReceptorsKeratinsMaleMiddle AgedAC133 AntigenAldehyde DehydrogenaseBiomarkers, TumorHyaluronan ReceptorsKeratinsPROM1 protein, human

Identifiers

PMID27789528
PMCPMC5407944

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.